A comparison between raltitrexed plus cisplatin and docetaxel plus cisplatin in concurrent chemoradiation for non-surgical esophageal squamous cell carcinoma |
| |
| Authors: | X. Xia Z. Liu B. Cai X. Di X. Sun X. Ge |
| |
| Affiliation: | 1. Department of Radiation Oncology, Jiangsu Province Hospital and Nanjing Medical University First Affiliated Hospital, 300, Guangzhou Road, Nanjing, Jiangsu, China;2. Department of Radiation Oncology, school of Nanjing Medical University, Jiangsu Province Hospital and Nanjing Medical University First Affiliated Hospital, 300, Guangzhou Road, Nanjing, Jiangsu, China;3. Department of Medicine Research, Chinese Academy of Medical Sciences & Peking Union Medical College Hospital of Skin Diseases and Institute of Dermatology, 12, Jiangwang Temple Street, Nanjing, Jiangsu, China;1. Department of radiation oncology, Jean-Perrin center, 63011 Clermont-Ferrand, France;2. Department of medical physics, Jean-Perrin center, Clermont-Ferrand, France;3. Clermont Auvergne university, INSERM, U1240 IMoST, 63000 Clermont-Ferrand, France;4. Department of pathology, Clermont Auvergne university, Jean-Perrin center, 63011 Clermont-Ferrand, France;5. Department of neurosurgery, Clermont-Ferrand hospital, 63003 Clermont-Ferrand, France;1. Service de radiothérapie, institut de cancérologie de Lorraine, 6, avenue de Bourgogne, 54511 Vand?uvre Lès Nancy, France;2. Service de radiophysique, institut de cancérologie de Lorraine, 6, avenue de Bourgogne, 54511 Vand?uvre Lès Nancy, France;3. Service de biostatistiques, institut de cancérologie de Lorraine, 6, avenue de Bourgogne, 54511 Vand?uvre Lès Nancy, France;4. Service de radiothérapie, centre Georges-François-Leclerc, 1, rue du Professeur-Marion, Dijon, France;5. Service de radiophysique, centre Georges-François-Leclerc, 1, rue du Professeur-Marion, Dijon, France;1. No. 2 Disease Aarea of Radiotherapy Abdomen and Pelvis, Shanxi Provincial Cancer Hospital, Taiyuan 030013, China;2. No. 3 Department of Gastroenterology, Shanxi Provincial Cancer Hospital, Taiyuan 030013, China;3. No. 3 Disease Aarea of Radiotherapy chest, Shanxi Provincial Cancer Hospital, Taiyuan 030013, China |
| |
| Abstract: | ![]()
PurposeChemoradiotherapy (CRT) is considered as a standard treatment for unresectable and inoperable esophageal cancer (EC) patients. However, no consensus has been reached regarding the optimal synchronous chemotherapy regimen and the best combination of radiotherapy and chemotherapy. The aim of this study was to evaluate the efficacy and toxicity of raltitrexed plus cisplatin and docetaxel plus cisplatin to find a safe and effective concurrent chemotherapy schedule.Patients and methodsOur retrospective study included 151 EC patients treated with raltitrexed and cisplatin (RP) (n = 90) or docetaxel and cisplatin (DP) (n = 61) from 2011 till 2018. Survival outcomes and treatment related toxicity were analyzed between the two groups.ResultsPFS and OS were 18 and 34 months in the RP group, while 13 and 20 months in the DP group (P = 0.118 and P = 0.270). The 1-, 2-, 3-year survival rates of the RP group were 71.1, 55.4 and 46.4%. For the DP group, these were 63.9, 44.3 and 37.6%, respectively. Compared with DP group, RP group received a superior CR rate (68.9% versus 52.5%, P = 0.041). There was a trend that the total number of toxic reactions in RP group was lower than that in DP group (P = 0.058).ConclusionsEven RP and DP groups have the similar survival outcomes and toxicity, raltitrexed/cisplatin get a higher complete response rate. Our study suggests that raltitrexed combined with cisplatin is a safe and effective concurrent chemotherapy regimen and it might be used as an alternative for cisplatin/5-FU and cisplatin/docetaxel in CCRT for EC patients. |
| |
| Keywords: | Esophageal cancer Chemoradiation Raltitrexed Docetaxel Survival analysis Cancer de l’?sophage Chimioradiation Raltitrexed Docetaxel Analyse de survie |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
